Be Alert for Rare Risks with Janus Kinase Inhibitors (Xeljanz, Etc)

April 2021

Risks with tofacitinib (Xeljanz, Xeljanz XR) are stacking up.

Xeljanz already has a boxed warning about serious infections...malignancy...thrombosis...and mortality.

Now FDA is alerting about more evidence that Xeljanz is associated with cancer (lung, etc)...and CV events (MI, etc).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote